long intergenic non-protein coding RNA 2514Genealiases: []
Q-omics provides the consensus-scored LINC02514 profile across patient tissues and cancer cell-line models. LINC02514 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC02514 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, LINC02514 RNA expression shows 5,826 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, PRAD, and STAD as cancer lineages where LINC02514 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02514 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02514 survival associations across molecular data types. LINC02514 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02514 RNA expression–survival associations across cancer types. High LINC02514 expression shows unfavorable associations in UCEC, MESO, ESCA, UCS, LUSC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC02514 RNA expression.
This table summarizes LINC02514 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02514. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02514 shows higher tumor expression in PRAD. The PRAD box plot shows higher LINC02514 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p = .045).
This table shows molecular features associated with LINC02514 in patient tissues and cancer cell lines. In patient samples, LINC02514 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
